Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension.

Badagliacca R, Papa S, Poscia R, Valli G, Pezzuto B, Manzi G, Torre R, Gianfrilli D, Sciomer S, Palange P, Naeije R, Fedele F, Vizza CD.

J Heart Lung Transplant. 2019 Mar;38(3):306-314. doi: 10.1016/j.healun.2018.11.015. Epub 2018 Dec 6.

PMID:
30581051
2.

Prognostic significance of the echocardiographic estimate of pulmonary hypertension and of right ventricular dysfunction in acute decompensated heart failure. A pilot study in HFrEF patients.

Badagliacca R, Ghio S, Correale M, Poscia R, Camporotondo R, Ferraretti A, Papa S, Pezzuto B, Petrone P, Torre R, Di Biase M, Novara P, Guida S, Vizza CD.

Int J Cardiol. 2018 Nov 15;271:301-305. doi: 10.1016/j.ijcard.2018.04.069. Epub 2018 Aug 27.

PMID:
30166068
3.

The importance of right ventricular function in patients with pulmonary arterial hypertension.

Badagliacca R, Papa S, Poscia R, Pezzuto B, Manzi G, Torre R, Fedele F, Vizza CD.

Expert Rev Respir Med. 2018 Oct;12(10):809-815. doi: 10.1080/17476348.2018.1515629. Epub 2018 Sep 6.

PMID:
30142003
4.

Oxygen supplementation for pulmonary arterial hypertension? Clues from the REVEAL registry.

Vizza CD, Badagliacca R.

J Heart Lung Transplant. 2018 Aug;37(8):941-942. doi: 10.1016/j.healun.2018.06.003. Epub 2018 Jun 13. No abstract available.

PMID:
30055811
5.

The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis.

Vizza CD, Badagliacca R, Messick CR, Rao Y, Nelsen AC, Benza RL.

Int J Cardiol. 2018 Mar 1;254:299-301. doi: 10.1016/j.ijcard.2017.12.016. Epub 2017 Dec 14.

6.

Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).

D'Alto M, Romeo E, Argiento P, Paciocco G, Prediletto R, Ghio S, Correale M, Lo Giudice F, Badagliacca R, Greco A, Vizza CD.

J Cardiovasc Med (Hagerstown). 2018 Jan;19(1):12-17. doi: 10.2459/JCM.0000000000000590.

PMID:
29215546
7.

Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension.

Badagliacca R, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F, Manzi G, Gianfrilli D, Ciciarello F, Sciomer S, Biondi-Zoccai G, Torre R, Fedele F, Vizza CD.

J Heart Lung Transplant. 2017 Oct 2. pii: S1053-2498(17)32041-7. doi: 10.1016/j.healun.2017.09.026. [Epub ahead of print]

PMID:
29107544
8.

Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension.

Badagliacca R, Raina A, Ghio S, D'Alto M, Confalonieri M, Correale M, Corda M, Paciocco G, Lombardi C, Mulè M, Poscia R, Scelsi L, Argiento P, Sciomer S, Benza RL, Vizza CD.

J Heart Lung Transplant. 2018 Mar;37(3):365-375. doi: 10.1016/j.healun.2017.08.009. Epub 2017 Aug 26.

PMID:
28912026
9.

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.

Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep.

10.

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.

Vizza CD, Jansa P, Teal S, Dombi T, Zhou D.

BMC Cardiovasc Disord. 2017 Sep 6;17(1):239. doi: 10.1186/s12872-017-0674-3.

11.

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.

Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, Olsson KM, Meyer K, Vizza CD, Vonk-Noordegraaf A, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Huscher D, Pittrow D, Rosenkranz S, Grünig E.

Eur Respir J. 2017 Aug 3;50(2). pii: 1700740. doi: 10.1183/13993003.00740-2017. Print 2017 Aug.

12.

Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension.

Badagliacca R, Papa S, Valli G, Pezzuto B, Poscia R, Reali M, Manzi G, Giannetta E, Berardi D, Sciomer S, Palange P, Fedele F, Naeije R, Vizza CD.

Eur Respir J. 2017 Jun 1;49(6). pii: 1601419. doi: 10.1183/13993003.01419-2016. Print 2017 Jun.

13.

Letter to the editor about the paper "Right ventricular dyssynchrony predicts clinical outcomes in patients with pulmonary hypertension" by Murata et al.

Badagliacca R, Reali M, Poscia R, Pezzuto B, Papa S, Mezzapesa M, Nocioni M, Valli G, Giannetta E, Sciomer S, Iacoboni C, Fedele F, Vizza CD.

Int J Cardiol. 2017 May 1;234:128. doi: 10.1016/j.ijcard.2017.01.081. No abstract available.

PMID:
28285628
14.

Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension.

Vizza CD, Sastry BK, Safdar Z, Harnisch L, Gao X, Zhang M, Lamba M, Jing ZC.

BMC Pulm Med. 2017 Feb 23;17(1):44. doi: 10.1186/s12890-017-0374-x.

15.

Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension.

Ghio S, D'Alto M, Badagliacca R, Vitulo P, Argiento P, Mulè M, Tuzzolino F, Scelsi L, Romeo E, Raineri C, Martino L, Tamburino C, Poscia R, Vizza CD.

Int J Cardiol. 2017 Mar 1;230:53-58. doi: 10.1016/j.ijcard.2016.12.099. Epub 2016 Dec 21.

PMID:
28038821
16.

Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.

Barillà F, Pelliccia F, Borzi M, Camici P, Cas LD, Di Biase M, Indolfi C, Mercuro G, Montemurro V, Padeletti L, Filardi PP, Vizza CD, Romeo F; 2015–2016 Board of the Italian Society of Cardiology.

J Cardiovasc Med (Hagerstown). 2017 Jan;18(1):1-9.

PMID:
27635937
17.

Echocardiography Combined With Cardiopulmonary Exercise Testing for the Prediction of Outcome in Idiopathic Pulmonary Arterial Hypertension.

Badagliacca R, Papa S, Valli G, Pezzuto B, Poscia R, Manzi G, Giannetta E, Sciomer S, Palange P, Naeije R, Fedele F, Vizza CD.

Chest. 2016 Dec;150(6):1313-1322. doi: 10.1016/j.chest.2016.07.036. Epub 2016 Aug 20.

PMID:
27554298
18.

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.

Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira Pena J, Denton CP.

Ann Rheum Dis. 2017 Feb;76(2):422-426. doi: 10.1136/annrheumdis-2015-209087. Epub 2016 Jul 25.

19.

Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.

Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D'Alto M, Olsson KM, Ulrich S, Scholtz W, Schulz U, Grünig E, Vizza CD, Staehler G, Bruch L, Huscher D, Pittrow D, Rosenkranz S.

J Am Coll Cardiol. 2016 Jul 26;68(4):368-78. doi: 10.1016/j.jacc.2016.05.047.

20.

Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.

Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P, Paciocco G, Tuzzolino F, Martino L, Beretta M, Callari A, Amaducci A, Badagliacca R, Poscia R, Meloni F, Refini RM, Geri P, Baldi S, Ghio S, D'Alto M, Argiento P, Sofia M, Guardamagna M, Pezzuto B, Vizza CD.

J Heart Lung Transplant. 2017 Feb;36(2):166-174. doi: 10.1016/j.healun.2016.04.010. Epub 2016 May 7.

PMID:
27329400
21.

Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension.

Badagliacca R, Poscia R, Pezzuto B, Papa S, Pesce F, Manzi G, Giannetta E, Raineri C, Schina M, Sciomer S, Parola D, Francone M, Carbone I, Fedele F, Vizza CD.

J Heart Lung Transplant. 2016 Nov;35(11):1321-1329. doi: 10.1016/j.healun.2016.04.006. Epub 2016 May 6.

PMID:
27241861
22.

Preoperative Evaluation of Patients Undergoing Lung Resection Surgery: Defining the Role of the Anesthesiologist on a Multidisciplinary Team.

Della Rocca G, Vetrugno L, Coccia C, Pierconti F, Badagliacca R, Vizza CD, Papale M, Melis E, Facciolo F.

J Cardiothorac Vasc Anesth. 2016 Apr;30(2):530-8. doi: 10.1053/j.jvca.2015.11.018. Epub 2015 Dec 1. Review. No abstract available.

PMID:
27013123
23.

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias.

Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A, Lange TJ, Claussen M, Grohé C, Klose H, Olsson KM, Zelniker T, Neurohr C, Distler O, Wirtz H, Opitz C, Huscher D, Pittrow D, Gibbs JS.

PLoS One. 2015 Dec 2;10(12):e0141911. doi: 10.1371/journal.pone.0141911. eCollection 2015.

24.

Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.

Peacock AJ, Zamboni W, Vizza CD.

Curr Med Res Opin. 2015;31(9):1793-807. doi: 10.1185/03007995.2015.1074890. Epub 2015 Aug 27. Review.

PMID:
26196225
25.

Right Intraventricular Dyssynchrony in Idiopathic, Heritable, and Anorexigen-Induced Pulmonary Arterial Hypertension: Clinical Impact and Reversibility.

Badagliacca R, Reali M, Poscia R, Pezzuto B, Papa S, Mezzapesa M, Nocioni M, Valli G, Giannetta E, Sciomer S, Iacoboni C, Fedele F, Vizza CD.

JACC Cardiovasc Imaging. 2015 Jun;8(6):642-52. doi: 10.1016/j.jcmg.2015.02.009. Epub 2015 May 14.

26.

Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension.

Stefanantoni K, Sciarra I, Vasile M, Badagliacca R, Poscia R, Pendolino M, Alessandri C, Vizza CD, Valesini G, Riccieri V.

Reumatismo. 2015 Mar 31;66(4):270-6. doi: 10.4081/reumatismo.2014.774.

27.

Circulating biomarkers in pulmonary arterial hypertension: update and future direction.

Pezzuto B, Badagliacca R, Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F, Vizza CD.

J Heart Lung Transplant. 2015 Mar;34(3):282-305. doi: 10.1016/j.healun.2014.12.005. Epub 2014 Dec 23. Review.

PMID:
25682555
28.

Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)".

Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper MM.

Circulation. 2014 Sep 16;130(12):e110-2. doi: 10.1161/CIRCULATIONAHA.114.010921. No abstract available.

PMID:
25223780
29.

'Real-life' information on pulmonary arterial hypertension: the iPHnet Project.

Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Parisi F, Badagliacca R, Fedele F, Vizza CD.

Curr Med Res Opin. 2014 Dec;30(12):2409-14. doi: 10.1185/03007995.2014.960514. Epub 2014 Sep 24.

PMID:
25180610
30.

Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries.

Schweikert B, Pittrow D, Vizza CD, Pepke-Zaba J, Hoeper MM, Gabriel A, Berg J, Sikirica M.

BMC Health Serv Res. 2014 Jun 9;14:246. doi: 10.1186/1472-6963-14-246.

31.

Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study.

Peacock AJ, Crawley S, McLure L, Blyth KG, Vizza CD, Poscia R, Francone M, Iacucci I, Olschewski H, Kovacs G, Vonk Noordegraaf A, Marcus JT, van de Veerdonk MC, Oosterveer FP.

Circ Cardiovasc Imaging. 2014 Jan;7(1):107-14. doi: 10.1161/CIRCIMAGING.113.000629. Epub 2013 Oct 30. Erratum in: Circ Cardiovasc Imaging. 2017 Feb;10 (2):.

PMID:
24173272
32.

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper MM.

Circulation. 2014 Jan 7;129(1):57-65. doi: 10.1161/CIRCULATIONAHA.113.004526. Epub 2013 Sep 30.

PMID:
24081973
33.

Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort.

Iudici M, Codullo V, Giuggioli D, Riccieri V, Cuomo G, Breda S, Manfredi A, Iannace N, D'Alto M, Ghio S, Rossi R, Vizza CD, Caporali R, Valesini G, Ferri C, Valentini G.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):31-6. Epub 2013 Jul 22.

PMID:
23910607
34.

Choosing the best first line oral drug agent in patients with pulmonary hypertension: evidence from a network meta-analysis.

Biondi-Zoccai G, D'Ascenzo F, Cannillo M, Welton NJ, Marra WG, Omedè P, Libertucci D, Fusaro E, Capriolo M, Perversi J, Fedele F, Frati G, Mancone M, Dinicolantonio JJ, Vizza CD, Moretti C, Gaita F.

Int J Cardiol. 2013 Oct 9;168(4):4336-8. doi: 10.1016/j.ijcard.2013.05.084. Epub 2013 Jun 10. No abstract available.

PMID:
23755974
35.

Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study.

Riccieri V, Vasile M, Iannace N, Stefanantoni K, Sciarra I, Vizza CD, Badagliacca R, Poscia R, Papa S, Mezzapesa M, Nocioni M, Valesini G.

Rheumatology (Oxford). 2013 Aug;52(8):1525-8. doi: 10.1093/rheumatology/ket168. Epub 2013 May 13.

PMID:
23671125
36.

Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry.

Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, Grunig E, Staehler G, Rosenkranz S, Halank M, Held M, Grohé C, Lange TJ, Behr J, Klose H, Wilkens H, Filusch A, Germann M, Ewert R, Seyfarth HJ, Olsson KM, Opitz CF, Gaine SP, Vizza CD, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Pittrow D.

Int J Cardiol. 2013 Sep 30;168(2):871-80. doi: 10.1016/j.ijcard.2012.10.026. Epub 2012 Nov 17.

PMID:
23164592
37.

Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey.

Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M, Preston IR, Barberà JA, Hassoun PM, Halank M, Jaïs X, Nickel N, Hoeper MM, Humbert M.

Eur Respir J. 2013 Jun;41(6):1302-7. doi: 10.1183/09031936.00089212. Epub 2012 Nov 8.

38.

Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.

Vizza CD, Fedele F, Pezzuto B, Rubin LJ.

Expert Opin Drug Saf. 2012 Nov;11(6):1003-11. doi: 10.1517/14740338.2012.714770. Epub 2012 Aug 4.

PMID:
22861496
39.

Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging.

Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, Naro F, Morano S, Fedele F, Lenzi A.

Circulation. 2012 May 15;125(19):2323-33. doi: 10.1161/CIRCULATIONAHA.111.063412. Epub 2012 Apr 11.

PMID:
22496161
40.

Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance.

Badagliacca R, Poscia R, Pezzuto B, Papa S, Nona A, Mancone M, Mezzapesa M, Nocioni M, Sciomer S, Valli G, Cedrone N, Fedele F, Vizza CD.

Cardiology. 2012;121(2):76-82. doi: 10.1159/000336172. Epub 2012 Mar 15.

PMID:
22433455
41.

Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral.

Badagliacca R, Pezzuto B, Poscia R, Mancone M, Papa S, Marcon S, Valli G, Sardella G, Ferrante F, Iacoboni C, Parola D, Fedele F, Vizza CD.

J Heart Lung Transplant. 2012 Apr;31(4):364-72. doi: 10.1016/j.healun.2011.12.011. Epub 2012 Jan 29.

PMID:
22289484
42.

Pregnancy outcomes in pulmonary arterial hypertension in the modern management era.

Jaïs X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, Vizza CD, Macdonald P, Humbert M, Hoeper MM.

Eur Respir J. 2012 Oct;40(4):881-5. Epub 2012 Jan 26.

43.

Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan.

Vizza CD, Letizia C, Badagliacca R, Poscia R, Pezzuto B, Gambardella C, Nona A, Papa S, Marcon S, Mancone M, Iacoboni C, Riccieri V, Volterrani M, Fedele F.

Int J Cardiol. 2013 Jul 15;167(1):220-4. doi: 10.1016/j.ijcard.2011.12.104. Epub 2012 Jan 20.

PMID:
22265324
44.

Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.

D'Alto M, Romeo E, Argiento P, D'Andrea A, Sarubbi B, Correra A, Scognamiglio G, Papa S, Bossone E, Calabrò R, Vizza CD, Russo MG.

Int J Cardiol. 2013 Apr 15;164(3):323-6. doi: 10.1016/j.ijcard.2011.07.009. Epub 2011 Jul 28.

PMID:
21802156
45.

Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension.

Calabrò P, Limongelli G, Maddaloni V, Vizza CD, D'Alto M, D'Alessandro R, Poscia R, Argiento P, Ziello B, Badagliacca R, Romeo E, Pacileo G, Russo MG, Fedele F, Calabrò R.

Intern Emerg Med. 2012 Oct;7(5):425-30. Epub 2011 Jul 20.

PMID:
21773759
46.

Unusual presentation for a patent ductus arteriosus.

Vizza CD, Badagliacca R, Poscia R, Gambardella C, Pezzuto B, Crescenzi E, Papa S, Fedele F.

Eur Respir Rev. 2009 Sep;18(113):174-6. doi: 10.1183/09059180.00003509.

47.

Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study.

Gruenig E, Michelakis E, Vachiéry JL, Vizza CD, Meyer FJ, Doelberg M, Bach D, Dingemanse J, Galiè N.

J Clin Pharmacol. 2009 Nov;49(11):1343-52. doi: 10.1177/0091270009341182. Epub 2009 Sep 15.

PMID:
19755415
48.

[2008 European guidelines on the diagnosis and management of pulmonary embolism: a new classification for a more comprehensive clinical evaluation].

D'Agostino C, Vizza CD.

G Ital Cardiol (Rome). 2009 May;10(5):348-9. Italian. No abstract available.

PMID:
19537443
49.

Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.

Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, Crescenzi E, Nona A, Benedetti G, Ferrante F, Sciomer S, Fedele F.

Regul Pept. 2008 Nov 29;151(1-3):48-53. doi: 10.1016/j.regpep.2008.08.002. Epub 2008 Aug 16.

PMID:
18796317
50.

Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension.

Valli G, Vizza CD, Onorati P, Badagliacca R, Ciuffa R, Poscia R, Brandimarte F, Fedele F, Serra P, Palange P.

Eur J Appl Physiol. 2008 Mar;102(4):417-24. Epub 2007 Nov 3.

PMID:
17978836

Supplemental Content

Loading ...
Support Center